Tumor immunology - Towards a paradigm of reciprocal research

Seminars in Cancer Biology

Volumn 12, Issue 1, 2002, Pages 73-80

  Drake, Charles G ^a   Pardoll, Drew M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer; Tolerance; Tumor immunology; Vaccine

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; PLATINUM; TUMOR VACCINE;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESEARCH; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; NONHUMAN; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNOLOGY; VACCINATION;

EID: 0036150874     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2001.0403     Document Type: Article

References (103)

1. Immunity to methylcholanthrene-induced sarcomas
2. The concept of immunological surveillance
3. Prostatic carcinoma. Correlation of histologic features of prognostic value with cytomorphology
4. Prostatic carcinoma: Some morphological features affecting prognosis
5. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases
6. Prognostic significance of histologic host response in cancer of the large bowel
7. Histologic correlates of virulence in ovarian adenocarcinoma. II. Morphologic correlates of host response
8. Lymphocytic infiltration and survival in rectal cancer
9. Time dependency of the influence of prognostic factors on relapse in breast cancer
10. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma
11. Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy
12. CD4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome
13. Inflammation and cancer: Back to Virchow?
14. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
15. T cell tolerance by clonal elimination in the thymus
16. T-cell receptor V beta use predicts reactivity and tolerance to Mlsa-encoded antigens
17. Timing of deletion of autoreactive V beta 6+ cells and down-modulation of either CD4 or CD8 on phenotypically distinct CD4+8+ subsets of thymocytes expressing intermediate or high levels of T cell receptor
18. Major histocompatibility complex-restricted recognition of retroviral superantigens by V beta 17+ T cells
19. T-cell apoptosis detected in situ during positive and negative selection in the thymus
20. A theory of self-nonself discrimination
21. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo
22. Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: Specific induction of a long-lived state of proliferative nonresponsiveness
23. T-cell clonal anergy
24. Ablation of 'tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice
25. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response
26. Selective and specific inhibition of 24 hour skin reactions in the guinea-pig. I. Immune deviation: Description of the phenomenon and the effect of splenectomy
27. Clonal deletion of thymocytes as a tumor escape mechanism
28. Deletion of idiotype (Id)-specific T cells in multiple myeloma
29. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies
30. Peripheral T cell tolerance as a tumor escape mechanism: Deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma
31. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice
32. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
33. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
34. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins
35. The molecular basis of T helper 1 and T helper 2 cell differentiation
36. Th2 subset dominance among peripheral blood T lymphocytes in patients with digestive cancers
37. Lung carcinoma: Analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry
38. Local expression of antiinflammatory cytokines in cancer
39. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma
40. T helper 2-dominant antilymphoma immune response is associated with fatal outcome
41. The clonal evolution of tumor cell populations
42. How much longer will tumour cells fool the immune system?
43. Antigen-processing machinery breakdown and tumor growth
44. Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y
45. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice
46. Identification of tumour rejection antigens recognized by T lymphocytes
47. Mouse tumor rejection antigens P815A and P815B: Two epitopes carried by a single peptide
48. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions
49. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma
50. Immune selection after antigen-specific immunotherapy of melanoma
51. Genes regulating MHC class I processing of antigen
52. Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome
53. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1- specific cytotoxic T lymphocytes
54. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions
55. Loss of transporter in antigen processing I transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer
56. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease
57. Studies on isoantigenic variation in mouse carcinomas and sarcomas
58. Further studies on isoantigenic variation in mouse carcinomas and sarcomas
59. Loss of HLA class I expression in prostate cancer: Implications for immunotherapy
60. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression
61. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance
62. Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma
63. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma
64. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: Association with disease progression
65. The HLA system. First of two parts
66. The central role of CD4(+) T cells in the antitumor immune response
67. The role of CD4+ T cell responses in antitumor immunity
68. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma
69. Flow cytometric investigation of immune-response-related surface molecules on human colorectal cancers
70. Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions
71. Association between HLA-expression and infiltration of immune cells in cervical carcinoma
72. Analysis of HLA-DR expression on keratinocytes in cervical neoplasia
73. Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas
74. HLA-DR antigen expression in colorectal carcinomas: Influence of expression by IFN-gamma in situ and its association with tumour progression
75. Cancer undefeated
76. Costimulatory wars: The tumor menace
77. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
78. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade
79. Autoaggression and tumor rejection: It takes more than self-specific T- cell activation
80. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes
81. Tumor rejection after direct costimulation of CD8+ T cells by B7- transfected melanoma cells
82. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma
83. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report
84. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
85. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
86. Bioactivity of human GM-CSF gene therapy in metastatic renal cell carcinoma and prostate cancer
87. Vaccination of melanoma patients with pep
88. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma
89. Cancer vaccines
90. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
91. Novel allogeneic granulocyte-macrophage colony-stimulating factor- secreting tumor vaccine for pancreatic cancer: A phase i trial of safety and immune activation
92. Interferon-gamma in the first-line therapy of ovarian cancer: A randomized phase III trial
93. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
94. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b
95. Initial sequencing and analysis of the human genome
96. The sequence of the human genome
97. Molecular classification of cutaneous malignant melanoma by gene expression profiling
98. Gene-expression profiles in hereditary breast cancer
99. Activation changes the spectrum but not the diversity of genes expressed by T cells
100. How self-tolerance and the immunosuppressive drug FK506 prevent B-cell mitogenesis